GT BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
GT BIOPHARMA, INC. (GTBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised of 1.52 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised · last filed 2026-08-14
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-06-30 was 400.00K shares, a 25.23% decline year-over-year.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2026-03-31 was 1.12M shares, a 272.04% increase year-over-year.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-12-31 was 8.75M shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for the quarter ending 2025-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2025 was 9.59M shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2023 was 96.67K shares.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2021 was 3.07M shares, a 1182.41% increase from fiscal 2020.
- GT BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, non-option equity instruments, exercised for fiscal 2020 was 239.71K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 400.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 1.52M shares 10-Q · filed 2026-08-14 | 10.28M shares derived: sum of 3 quarters · filed 2026-08-14 | 10.28M shares derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | 1.12M shares 10-Q · filed 2026-05-15 | 9.88M shares derived: sum of 2 quarters · filed 2026-05-15 | 9.88M shares derived: sum of 3 quarters · filed 2026-05-15 | 10.41M shares derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | 8.75M shares derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-02 | 8.75M shares derived: sum of 2 quarters · filed 2026-03-06 | 9.29M shares derived: sum of 3 quarters · filed 2026-03-06 | 9.59M shares 10-K · filed 2026-03-02 | |
| 2025-09-30 | 0.00 shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2026-03-06 | 535.00K shares derived: sum of 2 quarters · filed 2026-03-06 | 837.07K shares 10-Q/A · filed 2026-03-06 | ||
| 2025-06-30 | 535.00K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2026-03-06 | 837.07K shares 10-Q/A · filed 2026-03-06 | |||
| 2025-03-31 | 302.07K shares 10-Q · filed 2025-05-15 | ||||
| 2023-12-31 | -2.80M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -2.80M shares derived: sum of 2 quarters · filed 2025-02-21 | 96.67K shares 10-K · filed 2025-02-21 | ||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 2.90M shares 10-Q · filed 2023-11-01 | |||
| 2023-06-30 | 2.90M shares 10-Q · filed 2023-08-07 | ||||
| 2021-12-31 | 3.07M shares 10-K · filed 2023-03-30 | 3.08M shares 10-K · filed 2022-03-28 | |||
| 2021-03-31 | 94.42K shares 10-Q · filed 2021-05-17 | 334.13K shares derived: sum of 2 quarters · filed 2022-03-28 | 334.13K shares derived: sum of 3 quarters · filed 2022-03-28 | 334.13K shares derived: sum of 4 quarters · filed 2022-03-28 | |
| 2020-12-31 | 239.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 239.71K shares derived: sum of 2 quarters · filed 2022-03-28 | 239.71K shares derived: sum of 3 quarters · filed 2022-03-28 | 239.71K shares 10-K · filed 2022-03-28 | |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | 0.00 shares derived: sum of 2 quarters · filed 2020-11-13 | 0.00 shares 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | 0.00 shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | 0.00 shares 10-Q/A · filed 2020-08-18 | |||
| 2020-03-31 | 0.00 shares 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | 0.00 shares 10-K · filed 2021-04-16 | ||||
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-27 | ||||
| 2017-12-31 | 501.90K shares 10-K · filed 2019-03-29 | ||||
| 2016-12-31 | 42.03K shares 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |